The recent introduction and widespread use of glucagon-like peptide 1 receptor (GLP-1R) agonists presents new opportunities to study the therapeutic potential of these anti-obesity medications on nicotine dependence in individuals displaying T2D. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.